logo-loader
RNS
viewSynairgen PLC

Synairgen plc - Notice of Preliminary Results

RNS Number : 8735Q
Synairgen plc
03 March 2016
 

PRESS RELEASE

3 March 2016

 

SYNAIRGEN PLC

("Synairgen" or "the Company")

 

Notice of Preliminary Results

 

Southampton, UK, 3rd March 2016: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, will issue its preliminary results for the twelve month period ended 31st December 2015 on Tuesday 22nd March 2016.

 

A meeting for analysts will be held at 9:30am at the offices of finnCap at 60 New Broad St, London EC2M 1JJ.

ENDS

 

 

For further information, please contact:

 

Synairgen plc 

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

 

finnCap

Geoff Nash, James Thompson (Corporate Finance)

Stephen Norcross, Simon Johnson (Corporate Broking)

Tel: + 44 (0) 20 7220 0500

 

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Jessica Hodgson / Laura Thornton

[email protected]

Tel: +44 (0) 20 3709 5701

 

 

Notes for Editors

 

About Synairgen 

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology Biobank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging its scientific and clinical facilities at Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The Biobank of human samples is used in these models to increase confidence in the likelihood of successful drug development. Core to Synairgen's business strategy is the realisation of value via licensing transactions - validated in June 2014 by the SNG001 agreement formed with AstraZeneca. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORAKBDDBBKBNNK

Quick facts: Synairgen PLC

Price: 39.5

Market: AIM
Market Cap: £59.03 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18